Diabetes Pro Quarterly - Summer 2019 - 6

CLINICAL NEWS

2019 Standards of Medical Care in Diabetes Updated
In April, ADA's Standards of Medical Care in Diabetes, Section 5, Lifestyle Management, was updated through the
Living Standards process based on guidance included in the newly published "Nutrition Therapy for Adults With
Diabetes or Prediabetes: A Consensus Report." Another update was made primarily focused on cardiovascular and
renal health in patients with diabetes. Based on the results of REDUCE-IT (Reduction of Cardiovascular Events
with Icosapent Ethyl-Intervention Trial), Section 10, Cardiovascular Disease and Risk Management, now includes
a recommendation that icosapent ethyl be considered for patients with diabetes with atherosclerotic cardiovascular
disease or other cardiac risk factors who are on a statin with controlled LDL cholesterol but elevated triglycerides
(135-499 mg/dL) to reduce cardiovascular risk.
New information was also incorporated into the Standards of Care to reflect the findings of the DECLARE-TIMI 58 (Dapagliflozin
Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) trial, which examined the effects of the sodium-glucose
cotransporter 2 inhibitor dapagliflozin on cardiovascular and renal outcomes. Based on a revision to the prescribing information for
dapagliflozin, the approved use per estimated glomerular filtration rate was revised from ≥60 to ≥45 mL/min/1.73 m2.
These updates can be found on the Diabetes Care journal website (care.diabetesjournals.org) and on the Standards of Medical Care in
Diabetes page of the ADA website (professional.diabetes.org/SOC).

Update on Therapeutic Inertia Initiative
After the successful summit "Overcoming Therapeutic Inertia: Accelerating Diabetes Care For_Life" on November 28, 2018, the
summit's presenters and steering committee got to work with American Diabetes Association (ADA) staff to prepare a summary of the
summit proceedings for publication. After an open comment period which saw significant constructive and overwhelmingly positive feedback, the proceedings document was completed in mid-March. The 28-page document includes the key points made in each
presentation, recommendations for the creation of work groups to begin immediately solving key identified problems, and a high-level
roadmap of timing and next steps for the initiative.
At the time of this submission, the summary of proceedings had been mailed to all ADA professional members and was expected to be
delivered no later than April 12. It can also be found now on the project website at professional.diabetes.org/therapeuticinertia.
The Therapeutic Inertia Steering Committee met again on April 3 to formally start Phase 2 of this multi-year project. Next steps include
the formation of the work groups delineated in the summary of proceedings, determination of optimal ways to communicate ongoing
efforts, and review of feedback received during the open comment period.
This campaign is funded by founding sponsors Abbott, AstraZeneca, Merck, Novo Nordisk, and Sanofi and strategic sponsors Dexcom,
Janssen, Lilly, and Medtronic.

Diabetes Journal Takes New Steps to Increase
Transparency and Reproducibility
The editorial team of the American Diabetes Association's flagship
research journal, Diabetes, has recently announced three new policies to
increase the transparency and reproducibility of research published in
the journal. These policies are described in detail in a recently published
Diabetes editorial, which can be accessed at doi.org/10.2337/dbi19-0008.
The first two policies are intended to encourage transparent reporting
and sharing of 1) underlying data reported in a Diabetes research paper and 2) the resources
used to conduct the reported experiment(s). The third policy, which has been jointly adopted
by Diabetes and the European Association for the Study of Diabetes journal Diabetologia,
pertains specifically to studies that report on human islet data. This policy will require authors
to report important characteristics of the human islets used for the reported research.
The editors of Diabetes believe these policies represent important steps to help improve
the accessibility and reproducibility of research reported in the journal, encourage the
reporting and standardization of preparations and methods used by individual laboratories, and by extension facilitate comparisons among studies.
Prospective contributors to Diabetes are encouraged to read the editorial referenced
above to learn more about these policies and to send any questions or comments to
EditorialOffice@diabetes.org.
6

The Continuing Evolution
of Nutritional Therapy
for Diabetes
Last year, the American Diabetes
Association (ADA) issued a nationwide call for experts to review the
latest research on nutrition therapy
for diabetes. The resulting writing
group prepared a nutrition consensus
report intended to update and replace
the 2014 ADA nutrition position statement. The new nutrition consensus
report and four related featured articles were published in the May issue
of Diabetes Care in a special section
titled "The Continuing Evolution of
Nutritional Therapy for Diabetes."
Access the May issue at care.
diabetesjournals.org/content/42/5.
http://care.diabetesjournals.org http://professional.diabetes.org/SOC http://professional.diabetes.org/therapeuticinertia http://www.doi.org/10.2337/dbi19-0008 http://care.diabetesjournals.org/content/42/5
Diabetes Pro Quarterly - Summer 2019

Table of Contents for the Digital Edition of Diabetes Pro Quarterly - Summer 2019
